During Friday’s Afternoon trade, Shares of 21Vianet Group Inc (NASDAQ:VNET), lost -0.43% to $20.61.
21Vianet Group Inc (VNET) declared that Mr. Shang-Wen Hsiao, its Chief Financial Officer, has decided to resign from his current role and will serve as an advisor to the Board of Directors effective July 1, 2015. Mr. Hsiao has served as the Company’s CFO since June 2010. The Company also announced that Mr. Terry Wang will succeed Mr. Hsiao as Chief Financial Officer of 21Vianet.
21Vianet Group, Inc. provides carrier-neutral Internet data center services to Internet companies, government entities, blue-chip enterprises, and small- to mid-sized enterprises in the People’s Republic of China. It offers hosting and related services to house servers and networking equipment in its data centers, and connects them through a data transmission network; and other hosting related value-added services.
Shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA), declined -1.69% to $2.33, during its Afternoon trading session.
Synta Pharmaceuticals Corp. (SNTA) declared the publication in this month’s issue of Cancer Immunology Research of an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune checkpoint inhibition for cancer therapy. The review article, titled “Targeting Heat-Shock Protein 90 (Hsp90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy,” is accessible online at http://cancerimmunolres.aacrjournals.org. Synta is presently studying the Hsp90 inhibitor ganetespib in several randomized studies, counting the GALAXY-2 trial, a global, randomized, multi-center Phase 3 study of ganetespib and docetaxel for the second-line treatment of advanced non-small cell lung adenocarcinoma.
The review article describes preclinical findings that suggest that proteasomal degradation of cellular client proteins associated with Hsp90 inhibition may augment antitumor immune response through raised cellular antigen expression and subsequent improved T-cell recruitment and tumor-cell recognition. The review article also explains that client proteins affected by Hsp90 inhibition comprise oncogenes that may drive expression of Programmed Death-Ligand 1 (PD-L1), a key immune checkpoint. The resulting reduction of PD-L1 expression on tumor cells may enhance T-cell mediated cytotoxic activity and complement the activity of selective anti-PD-1 or anti-PD-L1 antibody therapies. This is supported by in vivo study results, where ganetespib was found to potentiate the antitumor efficacy of anti-PD-L1 antibody treatment. In these studies, the combination of ganetespib and an anti-PD-L1 antibody displayed significantly greater antitumor activity than either individual agent, in mouse models of both colon carcinoma and melanoma.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
Avid Technology, Inc. (NASDAQ:AVID), during its Friday’s Afternoon trading session decreased -4.03% to $13.70.
Avid(R) (AVID) declared it has achieved another noteworthy advance in the company’s Avid Everywhere(TM) vision by concluding its acquisition of Orad Hi-Tec Systems, a leading provider of state-of-the-art 3D real-time graphics, video servers, and related workflow administration solutions. The Orad product lines are highly complementary to the Avid MediaCentral Platform, and allow Avid to further deliver on its commitment to give media organizations and creative professionals more comprehensive workflows with greater choice, flexibility, and operational efficiency.
More than 600 customers worldwide presently rely on Orad’s cutting-edge technology to produce graphics, live events, and sports broadcasts. Avid plans to expand its portfolio and distribution network with Orad’s comprehensive line of news, channel branding, sports production and enhancement, elections and special events, virtual studios, video walls, and virtual advertisement products. With this expanded capability, media organizations on the Avid MediaCentral Platform should be able to reduce the burden of piecing together disparate fragmented workflows in their production environments, resulting in less complexity, fewer interoperability challenges, and greater efficiency and productivity.
Avid Technology, Inc. develops, markets, sells, and supports software and hardware for digital media content production, administration, and distribution in the United States, the other Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company offers various professional video creative tools, counting Media Composer product line, which is used to edit television programs, commercials, and films; NewsCutter option and iNews systems for news production; and Avid Symphony option that is used during post-production.
Finally, Iconix Brand Group Inc (NASDAQ:ICON), gained 1.70%, to $26.85.
Iconix Brand Group Inc (ICON) declared the appointment of David K. Jones as Executive Vice President and Chief Financial Officer. He will report directly to Chief Executive Officer, Neil Cole, and will lead all of the finance and technology functions for the Company.
Mr. Jones joins Iconix after twelve years with Penske Automotive Group (PAG), an international transportation services company. During his tenure, Mr. Jones served as Penske’s Executive Vice President and Chief Financial Officer, in addition to Chief Financial Officer of European Operations. Mr. Jones led the international accounting and finance functions, and was responsible for strengthening the company’s balance sheet through a series of large transactions. He was involved in all aspects of the business counting operations, financial reporting, budgeting, information technology, banking and treasury. Prior to Penske Automotive, Mr. Jones spent 11 years at Andersen LLP and is a Certified Public Accountant.
Iconix Brand Group, Inc., a brand administration company, owns, licenses, and markets a portfolio of consumer brands across women’s, men’s, entertainment, and home primarily in the United States and internationally. The company brand portfolio comprises Candies’, Bongo, Badgley Mischka, Joe Boxer, Rampage, Mudd, London Fog, Mossimo, Ocean Pacific, Danskin, Rocawear, Cannon, Royal Velvet, Fieldcrest, Charisma, Starter, Waverly, Ecko Unltd, Marc Ecko Cut & Sew, Zoo York, Sharper Image, Umbro, and Lee Cooper brand names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
